Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
4,157
datasets available to search
ShareScore release 0.9.0
Dataset results
4,157 results for “Survival.”
Dataset related to article "Muscle quality and not quantity as a predictor of survival in head and neck squamous cell carcinoma "
<p>This record contains raw data related to article "Muscle quality and not quantity as a predictor of survival in head and neck squamous cell carcinoma"</p><p><strong>Abstract</strong></p><p>Background: Sarcopenia is frequent in head and neck squamous cell carcinoma (HNSCC), as a consequence of malnutrition related to risk factors or tumoral mass. Treatment is associated with toxicities that lead to reduced calories intake and muscle mass wasting. Sarcopenia has been negatively associated with tumor control and survival outcomes.</p><p>Purpose: Our aim is to evaluate the prognostic impact of sarcopenia on overall survival (OS) and progression free survival (PFS) in HNSCC patients undergoing chemoradiation therapy within a prospective clinical trial of chemoradiation vs induction chemotherapy followed by radiation and cetuximab (INTERCEPTOR).</p><p>Materials and methods: On baseline CT or MRI, we investigated the association between OS and PFS with radiological markers of sarcopenia, measured at the third cervical vertebra level. We studied paravertebral skeletal muscles area (cm2), muscle density (HU), muscle index (cm2/m2), and intermuscular adipose tissue (IMAT) area (cm2).</p><p>Results: Imaging of 128 patients was evaluable. We found out that higher body mass index (BMI) was associated with better OS (p = 0.02), and PFS (p = 0.04). Skeletal muscle area (p = 0.02), and IMAT (p = 0.02) were negatively associated with PFS. IMAT was positively correlated with muscle area (Correlation coefficient 0.6, CI95% 0.47-0.7), and negatively associated with muscle density (Correlation coefficient -0.37, CI95% -0.53 - -0.18).</p><p>Conclusions: IMAT can be used as predictor of PFS in HNC patients undergoing chemoradiation therapy. The amount of intermuscular fat deposits induces alterations of muscle quality, without alterations of muscle quantity, influencing patients' prognosis.</p>
Dataset related to article "Total tumor volume as a predictor of survival in patients with multiple oligometastases treated with stereotactic ablative radiotherapy (SABR)"
<p>This record contains raw data related to article "Total tumor volume as a predictor of survival in patients with multiple oligometastases treated with stereotactic ablative radiotherapy (SABR)"</p><p><strong>Abstract</strong></p><p><strong>Background: </strong>Delivering stereotactic ablative radiotherapy (SABR) in patients with multiple oligometastases represents a challenge for clinical and technical reasons. We aimed to evaluate the outcome of patients affected by multiple oligometastases treated with SABR and the impact of tumor volume on survival.</p><p><strong>Materials and methods: </strong>We included all the patients treated with single course SABR for 3 to 5 extracranial oligometastases. All patients were treated with the volumetric modulated arc therapy (VMAT) technique with ablative intent. End-points of the analysis were overall survival (OS), progression free survival (PFS), local control (LC) and toxicity.</p><p><strong>Results: </strong>136 patients were treated from 2012 to 2020 on 451 oligometastases. Most common primary tumor was colorectal cancer (44.1%) followed by lung cancer (11.8%). A total of 3, 4 and 5 lesions were simultaneously treated in 102 (75.0%), 26 (19.1%), and 8 (5.9%) patients, respectively. Median total tumor volume (TTV) was 19.1 cc (range 0.6-245.1). With a median follow-up of 25.0 months, OS at 1 and 3 years was 88.4% and 50.2%, respectively. Increasing TTV was independent predictive factor of worse OS (HR 2.37, 95% CI 1.18-4.78, p = 0.014) and PFS (HR 1.63, 95% CI 1.05-2.54; p = 0.028). Median OS was 80.6 months if tumor volume was ≤ 10 cc (1 and 3 years OS rate 93.6% and 77.5%, respectively), and 31.1 months if TTV was higher than 10 cc (1 and 3 years OS rate 86.7% and 42.3%, respectively). Rates of LC at 1 and 3 years were 89.3% and 76.5%. In terms of toxicity, no grade 3 or higher toxicity was reported both in the acute and late settings.</p><p><strong>Conclusion: </strong>We demonstrated the impact of tumor volume on survival and disease control of patients affected by multiple oligometastases treated with single course SABR</p>
Dataset related to article "Myosteatosis Is Not Associated with Complications or Survival in HCC Patients Undergoing Trans Arterial Embolization"
<p>This record contains raw data related to article "Myosteatosis Is Not Associated with Complications or Survival in HCC Patients Undergoing Trans Arterial Embolization"</p><p> <strong>Abstract</strong></p><p>Alterations in nutritional status, in particular sarcopenia, have been extensively associated with a poor prognosis in cirrhotic patients regardless of the etiology of liver disease. Less is known about the predictive value of myosteatosis, defined as pathological fat infiltration into the skeletal muscle. We retrospectively analyzed a cohort of 151 cirrhotic patients with unresectable hepatocellular carcinoma (HCC) who underwent their first trans-arterial embolization (TAE) between 1 March 2011 and 1 July 2019 at our Institution. Clinical and biochemical data were collected. Sarcopenia was assessed using the L3-SMI method while myosteatosis with a dedicated segmentation suite (3D Slicer), using a single slice at an axial plane located at L3 and calculating the IMAC (Intramuscular Adipose Tissue Content Index). The sex-specific cut-off values for defining myosteatosis were IMAC > −0.44 in males and >−0.31 in females. In our cohort, 115 (76%) patients were included in the myosteatosis group; 128 (85%) patients had a coexistent diagnosis of sarcopenia. Patients with myosteatosis were significantly older and showed higher BMI than patients without myosteatosis. In addition, male gender and alcoholic- or metabolic-related cirrhosis were most represented in the myosteatosis group. Myosteatosis was not associated with a different HCC burden, length of hospitalization, complication rate, and readmission in the first 30 days after discharge. Overall survival was not influenced by the presence of myosteatosis</p>
Daset related to article:"Trends in survival of ALS from a population-based registry"
<p>Database including all raw data related to the publication entitled "Trends in survival of ALS from a population-based registry"</p>
Dataset related to article "Impact of active cancer on COVID-19 survival: a matchedanalysis on 557 consecutive patients at an Academic Hospital in Lombardy, Italy"
<p>This record contains raw data related to article "Impact of active cancer on COVID-19 survival: a matchedanalysis on 557 consecutive patients at an Academic Hospital in Lombardy, Italy"</p> <p><strong>Background: </strong> The impact of active cancer in COVID-19 patients is poorly defined; however, most studies showed a poorer outcome in cancer patients compared to the general population.</p> <p><strong>Methods: </strong> We analysed clinical data from 557 consecutive COVID-19 patients. Uni-multivariable analysis was performed to identify prognostic factors of COVID-19 survival; propensity score matching was used to estimate the impact of cancer.</p> <p><strong>Results: </strong> Of 557 consecutive COVID-19 patients, 46 had active cancer (8%). Comorbidities included diabetes (n = 137, 25%), hypertension (n = 284, 51%), coronary artery disease (n = 114, 20%) and dyslipidaemia (n = 122, 22%). Oncologic patients were older (mean age 71 vs 65, p = 0.012), more often smokers (20% vs 8%, p = 0.009), with higher neutrophil-to-lymphocyte ratio (13.3 vs 8.2, p = 0.046). Fatality rate was 50% (CI 95%: 34.9;65.1) in cancer patients and 20.2% (CI 95%: 16.8;23.9) in the non-oncologic population. Multivariable analysis showed active cancer (HR<sub>active</sub>: 2.26, p = 0.001), age (HR<sub>age>65years</sub>: 1.08, p < 0.001), as well as lactate dehydrogenase (HR<sub>LDH>248mU/mL</sub>: 2.42, p = 0.007), PaO2/FiO2 (HR<sub>continuous</sub>: 1.00, p < 0.001), procalcitonin (HR<sub>PCT>0.5ng/mL</sub>: 2.21, p < 0.001), coronary artery disease (HR<sub>yes</sub>: 1.67, p = 0.010), cigarette smoking (HR<sub>yes</sub>: 1.65, p = 0.041) to be independent statistically significant predictors of outcome. Propensity score matching showed a 1.92× risk of death in active cancer patients compared to non-oncologic patients (p = 0.013), adjusted for ICU-related bias. We observed a median OS of 14 days for cancer patients vs 35 days for other patients.</p> <p><strong>Conclusion: </strong> A near-doubled death rate between cancer and non-cancer COVID-19 patients was reported. Active cancer has a negative impact on clinical outcome regardless of pre-existing clinical comorbidities.</p>
Dataset for "Heat domes increase vulnerability of native stingless bees by simultaneously weakening key survival traits"
Open the record for dataset details and reuse information.
Floral diversity enhances winter survival of honey bee colonies across climatic regions
Open the record for dataset details and reuse information.
Impact of CALR Mutations on Treatment and Survival Outcomes in Myelofibrosis: A Call for Early Intervention and Tailored Treatment
Open the record for dataset details and reuse information.
[old/mistake] Data used in the GRL paper titled "Climatology of Tropical Cyclone Seed Frequency and Survival Rate in Tropical Cyclones"
<p>Data used in the GRL paper titled "Climatology of Tropical Cyclone Seed Frequency and Survival Rate in Tropical Cyclones" by Ikehata and Satoh</p> <p>Please download and decompress the zip file. We describe details of this dataset in "readme.txt".</p>
Raw data of the publication: Does moderate hyperkalemia influence survival in HF? Insights from the MECKI score data (Int J Cardiol . 2023 Jan 15;371:273-277. doi: 10.1016/j.ijcard.2022.09.030. Epub 2022 Sep 15)
<p><strong>Background: </strong>The prognostic role of moderate hyperkalemia in reduced ejection fraction (HFrEF) patients is still controversial. Despite this, it affects the use of renin-angiotensin-aldosterone system inhibitors (RAASi) with therapy down-titration or discontinuation.</p> <p><strong>Objectives: </strong>Aim of the study was to assess the prognostic impact of moderate hyperkalemia in chronic HFrEF optimally treated patients.</p> <p><strong>Methods and results: </strong>We retrospectively analyzed MECKI (Metabolic Exercise test data combined with Cardiac and Kidney Indexes) database, with median follow-up of 4.2 [IQR 1.9-7.5] years. Data on K<sup>+</sup> levels were available in 7087 cases. Patients with K<sup>+</sup> plasma level ≥ 5.6 mEq/L and < 4 mEq/L were excluded. Remaining patients were categorized into normal >4 and < 5 mEq/L (n = 4826, 68%) and moderately high ≥5.0 and ≤ 5.5 mEq/L (n = 496, 7%) K<sup>+</sup>. Then patients were matched by propensity score in 484 couplets of patients. MECKI score value was 7% [IQR 3.1-14.1%] and 7.3% [IQR 3.4-15%] (p = 0.678) in patients with normal and moderately high K<sup>+</sup> values while cardiovascular mortality events at two years follow-up were 41 (4.2%) and 33 (3.4%) (p = 0.333) in each group respectively.</p> <p><strong>Conclusions: </strong>Moderate hyperkalemia does not influence patients' outcome in a large cohort of ambulatory HFrEF patients.</p>
Impact of Wide Local Excision on Melanoma Patient Survival: A Population-Based Study
<p>Promoting standardization and quality assurance (QA) in oncology on the strength of real-world data is essential to ensure better patient outcomes. Wide excision after primary tumor biopsy is a fundamental step in the therapeutic pathway for cutaneous malignant melanoma (CMM). The aim of this population-based cohort study is to assess adherence to wide local excision in a cohort of patients diagnosed with CMM and the impact of this recommended procedure on overall and disease-specific survival.This retrospective cohort study concerns CMM patients diagnosed in the Veneto region (north-east Italy) in 2017, included in the high-resolution Veneto Cancer Registry, and followed up through linkage with the regional mortality registry up until February 29th, 2020. Using population-level real-world data, linking patient-level cancer registry data with administrative records of clinical procedures may shed light on the real-world treatment of CMM patients in accordance with current guidelines. After excluding TNM stage IV patients, a Cox regression analysis was performed to test whether the completion of a wide local excision was associated with a difference in melanoma-specific and overall survival, after adjusting for other covariates. No wide excision after the initial biopsy was performed in 9.7% of cases in our cohort of 1,305 patients. After adjusting for other clinical prognostic characteristics, Cox regression revealed that failure to perform a wide local excision raised the hazard ratio of death in terms of overall survival (HR = 4.80, 95% CI: 2.05-11.22, <em>p</em> < 0.001) and melanoma-specific survival (HR = 2.84, 95% CI: 1.04-7.76, <em>p</em> = 0.042). By combining clinical and administrative data, this study on real-world clinical practice showed that almost one in ten CMM patients did not undergo wide local excision surgery. Monitoring how diagnostic-therapeutic protocols are actually implemented in the real world may contribute significantly to promoting quality improvements in the management of oncological patients.</p>
Sex Differences in Cutaneous Melanoma: Incidence, Clinicopathological Profile, Survival, and Costs
<p>This study aims to provide a comprehensive overview of sex-related characteristics of cutaneous malignant melanoma (CMM), with special reference to its incidence, clinicopathological profile, overall survival, and treatment-related costs. This retrospective cohort study included all 1,279 CMM patients who were registered in 2015 in the Veneto Cancer Registry (a population-based registry including all 4,900,000 regional residents). The by-sex comparisons included tumor stage and site, histological subtype, and other clinical-pathological variables. A Cox regression analysis was used to test the association between sex and survival, adjusting for the main covariates. Treatment costs were calculated by linking patients with several administrative regional databases. Age-specific incidence rates were significantly higher for men among people >50 years old. For men, the trunk was the most common primary site (59.3%), whereas for women the lower limbs (32.1%) were the most common primary site, followed by the trunk (31.8%), which was lower than for men (<em>p</em> < 0.001). At presentation, the frequency of early stage CMM was higher among women, who also featured a significantly lower risk of death (<em>p</em> = 0.016), after adjusting for covariates. Men also incurred higher costs for melanoma treatment in the first year after their diagnosis. Among younger adults, CMM was more common in women, whereas among older adults, it was more common in men. Sex also influences patients' histopathological characteristics at diagnosis. Women had better overall survival after adjusting for demographic, pathological, and clinical profiles. The costs of treatment were also lower for women with CMM.</p>
REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicentre, single-arm, Phase IV itolizumab Trial: RESURRECT
<p>Datasets pertaining to the manuscript, Original Research, entitled “<strong>RE</strong>covery and <strong>SUR</strong>vival of patients with moderate to severe acute <strong>RE</strong>spiratory distress syndrome (ARDS) due to <strong>C</strong>OVID-19: a multicentre, single-arm, Phase IV Itolizumab <strong>T</strong>rial: <strong>RESURRECT</strong>” are submitted here. </p>
TP53 mutations are associated with improved survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: results from the MITO16A/MaNGO OV-2 study
<p><strong>PURPOSE</strong> Bevacizumab (BEV) is considered an effective treatment option for advanced ovarian carcinoma. However, to date, there are no biomarkers that define a BEV-responsive patient subpopulation.</p> <p><strong>METHODS</strong> In the context of the MITO16A/MaNGO OV-2 trial, a phase IV study of chemotherapy combined with BEV in first-line treatment of advanced ovarian carcinoma, we evaluated <em>TP53</em> mutations by next generation sequencing (NGS) and p53 protein expression by immunohistochemistry (IHC) on 202 and 311 cases, respectively. We further correlated NGS and IHC data with clinicopathological characteristics and survival of patients.</p> <p><strong>RESULTS</strong> <em>TP53</em> mutations of unknown function (named unclassified), mostly of the missense type, represented the majority of variants in our population (44.4%) and were associated with a significantly improved overall survival both in univariate (p=0.03, HR=0.43) and multivariate analysis (p=0.012, HR=0.39). Concordance between <em>TP53 </em>mutational analysis and protein expression was 91%. A trend toward improved OS was observed in patients with p53 IHC overexpression (HR=0.70, p=0.15) compared to p53 wild-type patients.</p> <p><strong>CONCLUSION </strong>Our results indicate that the presence of unclassified <em>TP53</em> mutations has favorable prognostic significance in patients with ovarian carcinoma receiving upfront BEV plus chemotherapy. In particular, unclassified missense <em>TP53</em> mutations characterize a subpopulation of patients with a significant survival advantage, independently of clinicopathological characteristics. Our findings warrant future investigations to confirm the prognostic impact of <em>TP53 </em>mutations in BEV-treated ovarian carcinoma patients and deserve to be assessed for their potential predictive role in future randomized clinical studies.</p>
Data and R code from: Survival analysis of wildlife cameras exposed to theft
<p>Data set an R code used to reproduce the analysis presented in Cardona et al. "Survival analysis of wildlife cameras exposed to theft".</p>
KLF5 controls subtype-independent highly interactive enhancers in pancreatic cancer to regulate cell survival [ChIPseq]
GEO Series GSE309860. Homo sapiens. 12 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Prolonged intra-neutrophil survival as an adaptive strategy of Staphylococcus aureus USA300 to the hospital environment
GEO Series GSE89394. Staphylococcus aureus subsp. aureus USA300. 48 samples. Type: Expression profiling by high throughput sequencing.
The AP-1 -BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma
GEO Series GSE107951. Homo sapiens. 10 samples. Type: Expression profiling by array.
Large neutral amino acid levels tune perinatal neuronal excitability and survival
GEO Series GSE218713. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
Bone Morphogenetic Protein Receptor Antagonists Inhibit Growth and Survival of Lung Cancer Cells Expressing Stem Cell Markers Oct4 or Nestin
GEO Series GSE49281. Homo sapiens. 4 samples. Type: Expression profiling by array.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.